BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare I&I: Systemic Lupus Erythematosus (SLE) Market Spotlight

October 03, 2019

Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease, characterized by abnormal immune activity resulting in the production of autoantibodies and associated immune complexes. The generation of a number of autoantibodies, particularly antinuclear antibodies (ANAs), is a hallmark of SLE. The disease can cause inflammation in multiple body systems either simultaneously or serially, including the skin, joints, kidneys, heart, lungs, and brain. The exact cause of SLE is unknown; however, genetic, environmental, and hormonal factors, as well as infectious agents, have been implicated in the development of the disease. SLE is a remitting and relapsing disease, and over time, flare-ups can lead to irreversible damage to organs. The clinical course and prognosis of SLE varies between patients. Lupus nephritis is a significant complication involving the kidneys that occurs in around a third of SLE patients, and is one of the causes of early mortality in these patients. The availability of better therapies, dialysis, and kidney transplantation has decreased mortality rates due to kidney disease. Instead, heart attacks and other cardiovascular diseases have emerged as the leading causes of mortality in lupus patients.

This Datamonitor Healthcare report contains a Market Spotlight module.
Indications Covered: Lupus Nephritis
Systemic Lupus Erythematosus (SLE)
Back to the top Back to the top